Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lipo-MERIT · 1 trial · 1 indication
Number of patients with adverse events, total number of adverse events, dose limiting toxicities
| Arm | Type | Description |
|---|---|---|
| Lipo-MERIT | EXPERIMENTAL | 7 dose escalation cohorts (3 +3 design) and 3 expanded cohorts |
| Name | Type | Description |
|---|---|---|
| Lipo-MERIT | BIOLOGICAL | vaccination |
Inclusion Criteria: * Cohort I: stage IV malignant melanoma (American joint committee on cancer (AJCC) 2009 melanoma classification) * Cohorts II-VII and expanded cohorts: stage IIIB-C, or stage IV of malignant melanoma (AJCC 2009 melanoma classification) \[only applicable until approval of protoco...
Top 20 of 51 competitors
Lipo-MERIT is an investigational cancer vaccine being studied for the treatment of advanced melanoma. It is administered intravenously and is currently in clinical development for patients with this type of skin cancer.
Lipo-MERIT is being developed by BioNTech SE, a biotechnology company traded on the NASDAQ under the ticker symbol BNTX. The company is conducting clinical trials to evaluate the safety and tolerability of this investigational therapy.
Lipo-MERIT is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial has been completed to assess its safety and tolerability in patients with advanced melanoma.
Lipo-MERIT has been studied in one clinical trial, identified as NCT02410733. This Phase 1 trial, titled 'Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma,' was completed and enrolled 119 participants in Germany.
Yes, Lipo-MERIT is classified as a monoclonal antibody. It is being developed as a cancer vaccine for melanoma and is administered intravenously. The drug is still in clinical development and has not been approved for commercial use.